Rare Thyroid Therapeutics is an innovative and integrated pharmaceutical company that focuses on developing treatments for serious diseases with significant unmet medical needs in the orphan drug segment. Their flagship product, Emcitate, is being developed to treat patients with monocarboxylate transporter 8 (MCT8) deficiency, a rare disease with no available treatment. Clinical trials and real-life studies have shown promising results in improving serum T3 levels and secondary clinical endpoints.

In the second quarter of 2023, Rare Thyroid Therapeutics plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) based on existing clinical data. Additionally, they will conduct a small study in the US to verify the results and intend to submit a new drug application (NDA) under the Fast-Track Designation granted by the FDA. Emcitate is also being investigated for its potential disease-modifying effects in very young MCT8 deficiency patients.

Rare Thyroid Therapeutics also has another drug candidate, Aladote, which aims to reduce the risk of acute liver injury associated with paracetamol overdose. Rare Thyroid Therapeutics is committed to addressing unmet medical needs and improving patients' lives